Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Contract revenue	$ 0	$ 1,961	$ 0	$ 2,717
Operating expenses
Research and development	9,528	3,759	17,118	7,106
General and administrative	6,319	3,460	12,509	6,067
Total operating expenses	15,847	7,219	29,627	13,173
Loss from operations	(15,847)	(5,258)	(29,627)	(10,456)
Other income (expense), net
Interest income and other, net	35	13	50	60
Interest expense and other, net		(169)		(357)
Change in estimated fair value of preferred unit warrant	0	(70)	0	(286)
Loss before income taxes	(15,812)	(5,484)	(29,577)	(11,039)
Income tax expense	(154)	(1)	(217)	(44)
Net loss and comprehensive loss	(15,966)	(5,485)	(29,794)	(11,083)
Net loss attributable to non-controlling interest	(8,342)	(5,485)	(15,947)	(11,083)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (7,624)		$ (13,847)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic	$ (0.31)		$ (0.60)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted	$ (0.31)		$ (0.60)
Common Class A [Member]
Other income (expense), net
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (7,624)		$ (13,847)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic	$ (0.31)		$ (0.60)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted	$ (0.31)		$ (0.60)
Weighted-average share outstanding basic	24,371		22,930
Weighted-average share outstanding diluted	24,371		22,930